Most Read Articles
Roshini Claire Anthony, 11 Dec 2020

Treatment with the nonsteroidal, selective mineralocorticoid receptor antagonist finerenone reduced chronic kidney disease (CKD) progression and cardiovascular (CV) event risk in patients with CKD and type 2 diabetes (T2D), according to the FIDELIO-DKD* study presented at ASN Kidney Week 2020.

Chronic coronary syndrome management: From guidelines to a personalised approach with Professor A. John Camm

18 Aug 2020
Guidelines on the treatment of chronic coronary syndrome increasingly recognise the need for individualised treatment. In this continuing medical education video Professor A. John Camm (Imperial College London, United Kingdom) shares his views on individualizing guideline-directed treatment based on a patient’s concomitant diseases, and the role of newer antianginal agents in this approach.
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 11 Dec 2020

Treatment with the nonsteroidal, selective mineralocorticoid receptor antagonist finerenone reduced chronic kidney disease (CKD) progression and cardiovascular (CV) event risk in patients with CKD and type 2 diabetes (T2D), according to the FIDELIO-DKD* study presented at ASN Kidney Week 2020.